What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.
PD-L1
cancer
checkpoint inhibitors
circulating tumor cells
exosomes
immunotherapy
liquid biopsy
prostate
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
06 Dec 2021
06 Dec 2021
Historique:
received:
14
10
2021
revised:
28
11
2021
accepted:
29
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Liquid biopsy is an accessible, non-invasive diagnostic tool for advanced prostate cancer (PC) patients, potentially representing a real-time monitoring test for tumor evolution and response to treatment through the analysis of circulating tumor cells (CTCs) and exosomes. We performed a systematic literature review (PRISMA guidelines) to describe the current knowledge about PD-L1 expression in liquid biopsies of PC patients: 101/159 (64%) cases revealed a variable number of PD-L1+ CTCs. Outcome correlations should be investigated in larger series. Nuclear PD-L1 expression by CTCs was occasionally associated with worse prognosis. Treatment (abiraterone, enzalutamide, radiotherapy, checkpoint-inhibitors) influenced PD-L1+ CTC levels. Discordance in PD-L1 status was detected between primary vs. metastatic PC tissue biopsies and CTCs vs. corresponding tumor tissues. PD-L1 is also released by PC cells through soluble exosomes, which could inhibit the T cell function, causing immune evasion. PD-L1+ PC-CTC monitoring and genomic profiling may better characterize the ongoing aggressive PC forms compared to PD-L1 evaluation on primary tumor biopsies/prostatectomy specimens (sometimes sampled a long time before recurrence/progression). Myeloid-derived suppressor cells and dendritic cells (DCs), which may have immune-suppressive effects in tumor microenvironment, have been found in PC patients circulation, sometimes expressing PD-L1. Occasionally, their levels correlated to clinical outcome. Enzalutamide-progressing castration-resistant PC patients revealed increased PD-1+ T cells and circulating PD-L1/2+ DCs.
Identifiants
pubmed: 34945784
pii: jpm11121312
doi: 10.3390/jpm11121312
pmc: PMC8709072
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Treat Res. 2018;175:87-104
pubmed: 30168118
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
J Immunother. 2019 Sep;42(7):269-273
pubmed: 31261165
Oncoimmunology. 2020 Feb 11;9(1):1721810
pubmed: 32117585
Urol Oncol. 2021 May;39(5):298.e13-298.e20
pubmed: 33712343
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616555
Oncotarget. 2017 Apr 18;8(16):26789-26801
pubmed: 28460462
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32269146
Microorganisms. 2021 Jan 03;9(1):
pubmed: 33401648
APMIS. 2018 Mar;126(3):267-272
pubmed: 29411910
Cancers (Basel). 2021 Sep 08;13(18):
pubmed: 34572754
Mol Cell. 2019 Jan 3;73(1):22-35.e6
pubmed: 30527665
Small. 2019 Dec;15(52):e1904378
pubmed: 31697036
Lancet. 2005 Jul 9-15;366(9480):107-8
pubmed: 16005318
Oncoimmunology. 2020 Apr 14;9(1):1744980
pubmed: 32363112
Clin Chem Lab Med. 2005;43(6):617-27
pubmed: 16006258
Cell Immunol. 2014 Jul;290(1):72-9
pubmed: 24908630
Ann Transl Med. 2019 Nov;7(21):610
pubmed: 32047771
J Immunother Cancer. 2019 Aug 14;7(1):218
pubmed: 31412954
J Immunol. 2012 Dec 15;189(12):5590-601
pubmed: 23152566
J Cancer. 2020 Jan 1;11(3):648-656
pubmed: 31942188
Clin Cancer Res. 2021 Jun 15;27(12):3360-3369
pubmed: 33568344
Theranostics. 2020 Jan 1;10(3):1033-1045
pubmed: 31938049
J Exp Med. 2019 Apr 1;216(4):982-1000
pubmed: 30872362
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
PLoS One. 2014 Aug 29;9(8):e105602
pubmed: 25170899
Oncoimmunology. 2014 Dec 13;3(9):e955331
pubmed: 25941611
Cancer Cell Int. 2020 Aug 15;20:394
pubmed: 32821247
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92
pubmed: 22474386
Ther Adv Med Oncol. 2020 Aug 25;12:1758835920936084
pubmed: 32922519
PLoS One. 2016 Nov 16;11(11):e0165089
pubmed: 27851748
Cancer Immunol Immunother. 2021 Mar;70(3):701-712
pubmed: 32909077
J Immunother Cancer. 2018 Sep 18;6(1):91
pubmed: 30227893
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Prostate. 2021 Jan;81(1):50-57
pubmed: 32986884
J Immunother Cancer. 2019 Nov 8;7(1):293
pubmed: 31703602
Prostate. 2019 Apr;79(5):498-505
pubmed: 30614027
J Drug Target. 2020 Jun;28(5):508-515
pubmed: 31865764
J Immunother Cancer. 2018 Nov 29;6(1):133
pubmed: 30486888
Mol Cancer. 2017 Apr 14;16(1):80
pubmed: 28410618
Diagnostics (Basel). 2021 Jan 29;11(2):
pubmed: 33572888
Cancers (Basel). 2021 Jul 01;13(13):
pubmed: 34282774
Phys Biol. 2019 Mar 22;16(3):036003
pubmed: 30763921
Pathol Res Pract. 2016 May;212(5):475-83
pubmed: 26876782
J Transl Med. 2020 May 28;18(1):214
pubmed: 32466781
Hum Pathol. 2018 Dec;82:131-139
pubmed: 30075156
Int J Surg Pathol. 2022 Apr;30(2):177-183
pubmed: 34180727
JAMA. 1994 Nov 2;272(17):1367-71
pubmed: 7933399
Cytopathology. 2020 May;31(3):185-192
pubmed: 31749241
Clin Genitourin Cancer. 2016 Apr;14(2):183-7
pubmed: 26775720
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
JCO Precis Oncol. 2017;2017:
pubmed: 29170762
Med Oncol. 2020 Jul 21;37(8):66
pubmed: 32696094
Cell Physiol Biochem. 2018;48(2):801-814
pubmed: 30032144
Mod Pathol. 2019 Mar;32(Suppl 2):1-173
pubmed: 30886285
Int J Mol Sci. 2019 Apr 13;20(8):
pubmed: 31013891
Cancer Lett. 2017 Oct 10;406:27-35
pubmed: 28797844
Cells. 2021 Nov 14;10(11):
pubmed: 34831388
Diagnostics (Basel). 2021 Feb 04;11(2):
pubmed: 33557386
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Am J Clin Exp Urol. 2019 Jun 15;7(3):159-169
pubmed: 31317055
Immunotargets Ther. 2020 Jul 27;9:115-130
pubmed: 32802803
Clin Genitourin Cancer. 2017 Oct;15(5):577-581
pubmed: 28461179
Theranostics. 2021 Mar 4;11(10):4809-4824
pubmed: 33754029
Cancers (Basel). 2021 Aug 18;13(16):
pubmed: 34439312
Medicine (Baltimore). 2020 May;99(19):e20124
pubmed: 32384491
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):184-193
pubmed: 31611635
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):454-463
pubmed: 30385408
Pathol Res Pract. 2019 Apr;215(4):828-831
pubmed: 30683477
J Contemp Brachytherapy. 2021 Aug;13(4):365-372
pubmed: 34484350
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Mol Ther Oncolytics. 2016 Dec 14;4:41-54
pubmed: 28345023
Bioconjug Chem. 2018 Jan 17;29(1):96-103
pubmed: 29125731
Anal Chem. 2018 Mar 20;90(6):3744-3751
pubmed: 29464943
Am J Pathol. 2018 Jun;188(6):1478-1485
pubmed: 29577933
Oncotarget. 2015 Jan 1;6(1):234-42
pubmed: 25428917
J Leukoc Biol. 2017 Aug;102(2):423-436
pubmed: 28533357
Oncoimmunology. 2018 Feb 14;7(6):e1431088
pubmed: 29872559
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33692219
Clin Cancer Res. 2020 Jul 1;26(13):3182-3192
pubmed: 32173650
Eur Urol Focus. 2019 Mar;5(2):192-196
pubmed: 28753812
Mol Cancer Res. 2018 Feb;16(2):243-255
pubmed: 29117944
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Clin Cancer Res. 2018 Dec 1;24(23):5948-5962
pubmed: 30337279
J Immunother Cancer. 2018 Dec 4;6(1):141
pubmed: 30514390
Int J Mol Sci. 2021 Nov 15;22(22):
pubmed: 34830209
Prostate. 2021 Feb;81(3):147-156
pubmed: 33368414
Clin Cancer Res. 2011 Feb 15;17(4):896-906
pubmed: 21106722
Cancer Cell. 2020 Oct 12;38(4):489-499.e3
pubmed: 32916128
Nature. 2015 May 7;521(7550):94-8
pubmed: 25924065
Ann Oncol. 2018 Aug 1;29(8):1807-1813
pubmed: 29992241
J Immunother Cancer. 2017 Feb 21;5:20
pubmed: 28239472
J Clin Pathol. 2018 Nov;71(11):1023-1027
pubmed: 30257853
PLoS One. 2018 Nov 6;13(11):e0206818
pubmed: 30399174
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
Front Oncol. 2021 Sep 09;11:681448
pubmed: 34568012
J Endovasc Ther. 2022 Jun;29(3):457-467
pubmed: 34569337
J Immunother. 2012 Feb-Mar;35(2):169-78
pubmed: 22306905
Oncotarget. 2016 Nov 29;7(48):79943-79955
pubmed: 27835597
Indian J Pathol Microbiol. 2019 Jul-Sep;62(3):405-412
pubmed: 31361228
Int J Biol Markers. 2018 Nov;33(4):540-544
pubmed: 30101629
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Nat Clin Pract Urol. 2009 Feb;6(2):76-85
pubmed: 19198621
Cell Biol Int. 2019 Jun;43(6):642-650
pubmed: 30958600
Prostate. 2018 Apr;78(5):353-364
pubmed: 29330929
J Cancer. 2019 Jun 2;10(14):3102-3111
pubmed: 31289580
Clin Genitourin Cancer. 2019 Apr;17(2):145-153.e5
pubmed: 30709785
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Pathol Res Pract. 2016 Oct;212(10):946-953
pubmed: 27499153
BMJ. 2003 Nov 8;327(7423):1083-4
pubmed: 14604930
BMC Pulm Med. 2019 Nov 19;19(1):216
pubmed: 31744552
Oncotarget. 2015 Dec 22;6(41):43267-80
pubmed: 26657115
Stain Technol. 1988 Jan;63(1):39-48
pubmed: 3258449
Cancers (Basel). 2021 Sep 12;13(18):
pubmed: 34572803
Urol Oncol. 2016 Nov;34(11):483.e9-483.e16
pubmed: 27658563
Diagnostics (Basel). 2021 Jan 07;11(1):
pubmed: 33430341
Anticancer Res. 2012 Aug;32(8):3507-13
pubmed: 22843938
Clin Cancer Res. 2017 Nov 15;23(22):6812-6822
pubmed: 28893901
Urol Oncol. 2019 May;37(5):297.e19-297.e31
pubmed: 30827759
APMIS. 2019 Aug;127(8):554-560
pubmed: 31127651
Mol Med Rep. 2018 May;17(5):7045-7054
pubmed: 29568923
Clin Cancer Res. 2019 Jun 1;25(11):3220-3228
pubmed: 30770348
Crit Rev Oncol Hematol. 2012 Mar;81(3):241-56
pubmed: 21680196
Fetal Pediatr Pathol. 2014 Apr;33(2):71-83
pubmed: 23883335
Medicine (Baltimore). 2019 Sep;98(38):e17257
pubmed: 31567999
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Clin Cancer Res. 2016 Apr 15;22(8):1969-77
pubmed: 26573597
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Int J Biol Sci. 2019 Mar 9;15(5):919-928
pubmed: 31182913
Mol Ther. 2020 Nov 4;28(11):2473-2487
pubmed: 32592689
Am J Clin Exp Urol. 2016 Jan 28;4(1):1-8
pubmed: 27069956
Cancer Res. 2017 Apr 15;77(8):2040-2051
pubmed: 28235763
Sci Rep. 2016 Jul 01;6:28910
pubmed: 27363678
Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625
pubmed: 29679564
Biomark Res. 2021 Feb 18;9(1):14
pubmed: 33602330
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Oncology. 2021;99(6):345-358
pubmed: 33735905
Mol Cancer. 2019 Oct 23;18(1):146
pubmed: 31647023
J Geriatr Phys Ther. 2022 Oct-Dec 01;45(4):E169-E180
pubmed: 34570041
Mol Imaging Biol. 2020 Dec;22(6):1553-1561
pubmed: 32813112
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
FEBS Open Bio. 2019 Jun;9(6):1063-1070
pubmed: 31090214
J Clin Med. 2020 Aug 06;9(8):
pubmed: 32781666
Urol Oncol. 2016 May;34(5):235.e11-6
pubmed: 26795608
Eur Urol. 2017 Nov;72(5):828-834
pubmed: 28818355
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499258
Br J Cancer. 2020 Sep;123(7):1089-1100
pubmed: 32641865
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
Cancer Microenviron. 2018 Jun;11(1):41-49
pubmed: 29357011
Cell Death Dis. 2019 Aug 20;10(9):631
pubmed: 31431617
Int J Cancer. 2012 Dec 1;131(11):2528-36
pubmed: 22473715
Mol Oncol. 2018 Mar;12(3):269-286
pubmed: 28865178
Eur Urol Focus. 2018 Jan;4(1):75-79
pubmed: 28753790
BMC Med Genomics. 2017 Dec 06;10(1):74
pubmed: 29212506
Diagnostics (Basel). 2021 Apr 14;11(4):
pubmed: 33919741
Can Urol Assoc J. 2021 Dec;15(12):E664-E671
pubmed: 34171214
Oncotarget. 2016 Jul 26;7(30):48625-48643
pubmed: 26980749
Prostate. 2019 Feb;79(3):320-330
pubmed: 30488530
Ann Med. 2021 Dec;53(1):1676-1687
pubmed: 34569391
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668490
J BUON. 2018 Nov-Dec;23(6):1796-1802
pubmed: 30610805
Diagnostics (Basel). 2021 Aug 25;11(9):
pubmed: 34573885
Int J Mol Sci. 2021 Nov 14;22(22):
pubmed: 34830179
Urol Int. 2022;106(10):979-991
pubmed: 34569529
Lab Chip. 2015 May 21;15(10):2278-86
pubmed: 25876237
BMC Cancer. 2021 Apr 27;21(1):468
pubmed: 33906629
Cancer Immunol Res. 2020 Jul;8(7):844-850
pubmed: 32321776
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Oncogene. 2020 May;39(19):3939-3951
pubmed: 32203167
J Immunother Cancer. 2019 Oct 25;7(1):277
pubmed: 31653272
Oncoimmunology. 2014 Dec 21;3(11):e963413
pubmed: 25914862
Asian J Androl. 2017 Aug 22;:
pubmed: 28836508
Nat Med. 2020 Jan;26(1):39-46
pubmed: 31873309
Urologiia. 2019 Sep;(4):51-57
pubmed: 31535805
Clin Cancer Res. 2021 Jun 1;27(11):3253-3264
pubmed: 33753455
BMC Cancer. 2021 Apr 13;21(1):399
pubmed: 33849473
Biochem J. 2020 Nov 27;477(22):4367-4381
pubmed: 33094805
Cancer Immunol Res. 2014 Oct;2(10):988-99
pubmed: 25189164
Int J Mol Sci. 2021 Nov 15;22(22):
pubmed: 34830196
Theranostics. 2017 Aug 22;7(14):3585-3594
pubmed: 28912897
Biomed Pharmacother. 2021 May;137:111339
pubmed: 33550044
APMIS. 2017 Sep;125(9):844-848
pubmed: 28543860
Sci Transl Med. 2010 Mar 31;2(25):25ra23
pubmed: 20424012
Lancet Oncol. 2014 Apr;15(4):406-14
pubmed: 24636208
Oncotarget. 2016 Aug 16;7(33):53309-53320
pubmed: 27462860
Mol Cancer Res. 2016 Jun;14(6):539-47
pubmed: 26951228
Cancer Gene Ther. 2019 Nov;26(11-12):388-399
pubmed: 30607005
J Clin Epidemiol. 2021 Jun;134:103-112
pubmed: 33577987
J Clin Invest. 2018 Oct 1;128(10):4441-4453
pubmed: 30179225
Clin Cancer Res. 2020 Sep 15;26(18):5019-5035
pubmed: 32605911
APMIS. 2020 Mar;128(3):191-200
pubmed: 31697865
Int J Gynecol Pathol. 2021 Sep 1;40(5):441-447
pubmed: 33252401
Sci Adv. 2020 Sep 18;6(38):
pubmed: 32948597
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Target Oncol. 2016 Jun;11(3):345-51
pubmed: 26566945
Mol Med Rep. 2019 Nov;20(5):4244-4252
pubmed: 31545446
Nat Cancer. 2021 Apr;2(4):444-456
pubmed: 33899001
Oncotarget. 2016 Mar 1;7(9):10557-67
pubmed: 26859684
Eur Urol. 2011 Nov;60(5):897-904
pubmed: 21802835
Trends Cancer. 2021 Sep;7(9):837-846
pubmed: 33903073
Cancer Biother Radiopharm. 2014 May;29(4):153-61
pubmed: 24693958
Exp Cell Res. 2018 Mar 1;364(1):113-123
pubmed: 29408565
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32
pubmed: 26260996
JAMA Oncol. 2015 Aug;1(5):582-91
pubmed: 26181238
APMIS. 2018 Sep;126(9):771-776
pubmed: 30160016
J Invest Dermatol. 2010 Oct;130(10):2440-7
pubmed: 20535130
Oncotarget. 2017 Dec 04;9(12):10284-10293
pubmed: 29535806
Cancers (Basel). 2021 Feb 17;13(4):
pubmed: 33671249
Mol Oncol. 2021 May;15(5):1358-1375
pubmed: 33338321
Zhonghua Nan Ke Xue. 2016 Nov;22(11):963-967
pubmed: 29281201
Medicine (Baltimore). 2021 Jun 04;100(22):e25863
pubmed: 34087828
Oncotarget. 2017 Jul 18;8(29):47474-47489
pubmed: 28537896
Oncotarget. 2017 Jun 21;8(32):53518-53530
pubmed: 28881828
Aging Cell. 2019 Dec;18(6):e13027
pubmed: 31493351
Oncotarget. 2017 Aug 18;8(42):72755-72772
pubmed: 29069824
Front Biosci (Landmark Ed). 2017 Jun 1;22(10):1682-1696
pubmed: 28410139
Cells. 2021 Nov 14;10(11):
pubmed: 34831389
Oncotarget. 2018 May 22;9(39):25586-25596
pubmed: 29876010
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
Oncoimmunology. 2016 Mar 28;5(6):e1165377
pubmed: 27471641
Nat Commun. 2021 Mar 3;12(1):1426
pubmed: 33658518
J Urol. 2017 Jan;197(1):135-142
pubmed: 27436429
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Mol Med Rep. 2018 Jun;17(6):8111-8120
pubmed: 29693186
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Cancer Immunol Res. 2015 Aug;3(8):946-55
pubmed: 26041735
Breast Cancer Res. 2010;12(4):R48
pubmed: 20626886
Arch Pathol Lab Med. 2016 Aug;140(8):825-9
pubmed: 27195432
Int J Cancer. 2019 Jun 15;144(12):3099-3110
pubmed: 30537104
Sci Rep. 2019 Jul 23;9(1):10662
pubmed: 31337863
G Ital Cardiol (Rome). 2013 Jun;14(6):481-4
pubmed: 23748548